|
Parameters
|
Number of patients /recurrence/death
|
Disease-free survival
|
Overall survival
|
|---|
|
Mean survival (95 % CI) months
|
p value
|
Mean survival (95 % CI) months
|
p value
|
|---|
|
PD-L1 (28-8) (T)
| | |
N/A
| |
0.967
|
|
Negative
|
191/16/17
|
N/A
| |
91 (87–95)
| |
|
Positive
|
27/0/2
|
N/A
| |
59 (54–64)
| |
|
PD-L1 (E1L3N) (T)
| | |
N/A
| |
0.647
|
|
Negative
|
186/16/17
|
N/A
| |
90 (86–95)
| |
|
Positive
|
32/0/2
|
N/A
| |
91 (84–98)
| |
|
PD-L1 (28-8) (I)
| | |
0.043
| |
0.021
|
|
Negative
|
138/14/17
|
89 (84–93)
| |
87 (82–92)
| |
|
Positive
|
80/2/2
|
97 (94–100)
| |
97 (94–100)
| |
|
PD-L1 (E1L3N) (I)
| | |
0.761
| |
0.255
|
|
Negative
|
136/11/15
|
91 (87–95)
| |
88 (84–93)
| |
|
Positive
|
82/5/4
|
94 (89–98)
| |
95 (90–99)
| |
|
PD-L1 (SP142) (I)
| | |
0.191
| |
0.387
|
|
Negative
|
176/15/17
|
90 (86–94)
| |
89 (85–93)
| |
|
Positive
|
42/1/2
|
97 (93–101)
| |
95 (89–100)
| |
- Italics represents p < 0.05
-
T tumor cell, I immune cell
